biomodal Overview

  • Year Founded
  • 2012

Year Founded

  • Status
  • Private

  • Employees
  • 111

Employees

  • Latest Deal Type
  • Series D

  • Latest Deal Amount
  • $87.9M

  • Investors
  • 12

biomodal General Information

Description

Developer of a DNA sequencing technology designed to offer advanced medicines, diagnostics, and personalized treatments. The company's technology can easily integrate into existing sequencing and compute platforms and offer more information to be read from DNA, enabling medical professionals to gain complete genetic and epigenetic methylation information from the DNA library in a single workflow.

Contact Information

Website
www.biomodal.com
Formerly Known As
Newincco 1171, Cambridge Epigenetix
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Chesterford Research Park
  • The Trinity Building
  • Cambridge CB10 1XL
  • England, United Kingdom
+44 01223
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Other Healthcare Technology Systems
Vertical(s)
Digital Health, HealthTech, Life Sciences, Oncology
Corporate Office
  • Chesterford Research Park
  • The Trinity Building
  • Cambridge CB10 1XL
  • England, United Kingdom
+44 01223

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

biomodal Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series D) 02-Nov-2021 $87.9M Completed Generating Revenue
6. Later Stage VC (Series C) 09-May-2018 Completed Generating Revenue
5. Early Stage VC (Series B) 14-Mar-2016 Completed Generating Revenue
4. Early Stage VC (Series A1) 29-Oct-2014 Completed Generating Revenue
3. Early Stage VC 18-Nov-2013 Completed Generating Revenue
2. Seed Round 14-Jan-2013 $887K $887K Completed Generating Revenue
1. University Spin-Out 01-Jan-2012 Completed Generating Revenue
To view biomodal’s complete valuation and funding history, request access »

biomodal Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary
D Preferred
D Preferred
D Preferred
C Preferred
C Preferred
B Preferred
A Preferred
A1 Preferred 604,543 $0.000137 $7.53 $7.53 $7.53 6.27%
Ordinary 274,266 $0.000137 $4.99 $4.99 $4.99 2.84%
To view biomodal’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

biomodal Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a DNA sequencing technology designed to offer advanced medicines, diagnostics, and personalized treatments.
Discovery Tools (Healthcare)
Cambridge, United Kingdom
111 As of 2026

Oxford, United Kingdom
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

biomodal Competitors (7)

One of biomodal’s 7 competitors is Oxford Nanopore Technologies, a Formerly VC-backed company based in Oxford, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oxford Nanopore Technologies Formerly VC-backed Oxford, United Kingdom
Hurdle (Decision/Risk Analysis) Venture Capital-Backed London, United Kingdom
Diagenode Formerly VC-backed Seraing, Belgium
Illumina Formerly VC-backed San Diego, CA
Verge Labs Venture Capital-Backed San Francisco, CA
You’re viewing 5 of 7 competitors. Get the full list »

biomodal Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

biomodal Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Jameel Investment Management Company Corporate Venture Capital Minority
Temasek Holdings Sovereign Wealth Fund Minority
Third Point Asset Manager Minority
Third Point Ventures Venture Capital Minority
Ahren Innovation Capital Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

biomodal FAQs

  • When was biomodal founded?

    biomodal was founded in 2012.

  • Where is biomodal headquartered?

    biomodal is headquartered in Cambridge, United Kingdom.

  • What is the size of biomodal?

    biomodal has 111 total employees.

  • What industry is biomodal in?

    biomodal’s primary industry is Discovery Tools (Healthcare).

  • Is biomodal a private or public company?

    biomodal is a Private company.

  • What is the current valuation of biomodal?

    The current valuation of biomodal is .

  • What is biomodal’s current revenue?

    The current revenue for biomodal is .

  • How much funding has biomodal raised over time?

    biomodal has raised $145M.

  • Who are biomodal’s investors?

    Jameel Investment Management Company, Temasek Holdings, Third Point, Third Point Ventures, and Ahren Innovation Capital are 5 of 12 investors who have invested in biomodal.

  • Who are biomodal’s competitors?

    Oxford Nanopore Technologies, Hurdle (Decision/Risk Analysis), Diagenode, Illumina, and Verge Labs are some of the 7 competitors of biomodal.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process